AtriCure, Inc. (ATRC)
NASDAQ: ATRC · IEX Real-Time Price · USD
24.17
-0.50 (-2.03%)
At close: Jul 19, 2024, 4:00 PM
24.08
-0.09 (-0.37%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
AtriCure Revenue
AtriCure had revenue of $414.60M in the twelve months ending March 31, 2024, with 18.70% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $108.85M with 16.43% year-over-year growth. In the year 2023, AtriCure had annual revenue of $399.25M with 20.84% growth.
Revenue (ttm)
$414.60M
Revenue Growth
+18.70%
P/S Ratio
2.82
Revenue / Employee
$394,859
Employees
1,050
Market Cap
1.17B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.25M | 68.87M | 20.84% |
Dec 31, 2022 | 330.38M | 56.05M | 20.43% |
Dec 31, 2021 | 274.33M | 67.80M | 32.83% |
Dec 31, 2020 | 206.53M | -24.28M | -10.52% |
Dec 31, 2019 | 230.81M | 29.18M | 14.47% |
Dec 31, 2018 | 201.63M | 26.91M | 15.40% |
Dec 31, 2017 | 174.72M | 19.61M | 12.64% |
Dec 31, 2016 | 155.11M | 25.35M | 19.54% |
Dec 31, 2015 | 129.76M | 22.30M | 20.75% |
Dec 31, 2014 | 107.45M | 25.57M | 31.22% |
Dec 31, 2013 | 81.89M | 11.64M | 16.57% |
Dec 31, 2012 | 70.25M | 5.85M | 9.08% |
Dec 31, 2011 | 64.40M | 5.40M | 9.14% |
Dec 31, 2010 | 59.01M | 4.47M | 8.20% |
Dec 31, 2009 | 54.53M | -723.47K | -1.31% |
Dec 31, 2008 | 55.26M | 6.95M | 14.38% |
Dec 31, 2007 | 48.31M | 10.07M | 26.32% |
Dec 31, 2006 | 38.24M | 7.29M | 23.54% |
Dec 31, 2005 | 30.96M | 11.80M | 61.60% |
Dec 31, 2004 | 19.16M | 9.36M | 95.63% |
Dec 31, 2003 | 9.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.42B |
Omnicell | 1.10B |
Artivion | 368.21M |
Maravai LifeSciences Holdings | 274.10M |
Xencor | 162.18M |
Establishment Labs Holdings | 155.79M |
Prothena Corporation | 89.25M |
Ocular Therapeutix | 59.84M |
ATRC News
- 13 days ago - AtriCure to Announce Second Quarter 2024 Financial Results - Business Wire
- 2 months ago - AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference - Business Wire
- 2 months ago - AtriCure Reports First Quarter 2024 Financial Results - Business Wire
- 2 months ago - AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference - Business Wire
- 3 months ago - AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management - Business Wire
- 3 months ago - AtriCure to Announce First Quarter 2024 Financial Results - Business Wire
- 4 months ago - AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Business Wire
- 5 months ago - AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results - Business Wire